CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Many patients may have to switch obesity drugs now that CVS Caremark opted to stop offering tirzepatide (Zepbound) in favor of semaglutide (Wegovy), despite the latter yielding less weight loss.

Caremark negotiated an undisclosed lower ... meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly.

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...